RxDoctor Payments DataLook up a doctor →

Claressa Rosacina, NP

Adult Health · Houston, TXNPI 1205236718

Payments from drug & device makers

$16,528in general payments, 2019–2025

Across 592 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Johnson & Johnson$2K
  • AstraZeneca$860
  • Seagen Inc.$744
  • Merck$738
  • Bristol Myers Squibb$702
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$3752%
  • Food & beverage$14,27986%
  • Education$1,3768%
  • Other$4993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis90$1,974
Johnson & Johnson(2 entities)61$1,897
AstraZeneca(2 entities)36$860
Seagen Inc.21$744
Merck34$738
Bristol Myers Squibb33$702
Lilly USA, LLC21$671
E.r. Squibb & Sons, L.L.C.19$638
AbbVie16$601
Amgen22$597
Janssen Scientific Affairs, LLC3$597
Incyte Corporation21$522
Beigene USA, Inc.5$363
Astellas Pharma US Inc14$361
US Oncology Corporate, Inc.3$344
Sanofi14$307
GSK12$286
Myriad Genetic Laboratories, Inc.3$253
Eisai Inc.11$238
Pharmacyclics LLC, An Abbvie Company8$195
ADC Therapeutics America, Inc.4$190
Bayer9$187
Jazz Pharmaceuticals Inc.6$182
Pfizer8$182
Rigel Pharmaceuticals, Inc.8$178
Genentech USA, Inc.8$166
Taiho Oncology, Inc.8$154
Deciphera Pharmaceuticals Inc.5$141
Regeneron Healthcare Solutions, Inc.2$138
Morphosys, US Inc.7$136
TG Therapeutics, Inc.2$134
Takeda Pharmaceuticals U.S.A., Inc.5$112
ASD Specialty Healthcare, LLC1$93
Kyowa Kirin, Inc.5$90
Apellis Pharmaceuticals, Inc.3$90
Gilead(2 entities)4$86
Sanofi-aventis U.S. LLC1$85
Servier Pharmaceuticals LLC4$79
CTI Biopharma Corp.3$74
Daiichi Sankyo Inc.3$72
Springworks Therapeutics, Inc.3$71
Blueprint Medicines Corporation2$64
Ipsen Biopharmaceuticals, Inc3$62
Stemline Therapeutics Inc.3$58
Pharming Healthcare, Inc.2$51
Exelixis Inc.3$50
Tersera Therapeutics LLC2$50
G1 Therapeutics, Inc.2$49
Tempus AI, Inc2$47
Acceleron Pharma, Inc.2$46
Array Biopharma Inc2$44
EMD Serono, Inc.2$44
Sobi, Inc1$44
Myovant Sciences Inc.2$42
Karyopharm Therapeutics Inc.2$41
Mirati Therapeutics, Inc.2$39
Legend Biotech USA Inc.1$36
Alnylam Pharmaceuticals Inc.1$24
Dendreon Pharmaceuticals LLC1$22
AVEO Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,528 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas →

Medicare billing

Part B allowed, 2024
$4,099
Medicare patients
34
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult health in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →